info@seagull-health.com
SeagullHealth
search
Sparsentan(Filspari)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Filspari(Sparsentan) Instructions:Uses,Dosage, Side Effects
Sparsentan, marketed as FILSPARI, is used for the management of primary IgAN, a condition that causes kidney damage. By antagonizing both endothelin type A and angiotensin II type 1 receptors, it helps to slow kidney function decline and reduce proteinuria in affected patients.
It is important for patients to undergo regular monitoring of liver function and to follow contraception guidelines due to the drug's risks of hepatotoxicity and embryo-fetal toxicity. Sparsentan offers a promising therapy for IgAN, but its use requires strict adherence to safety protocols to minimize the risk of adverse effects.
FILSPARI® (Sparsentan) is indicated for the treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney disorder that leads to nephrotic syndrome. This medication is specifically used in patients who have FSGS and are at risk of progressive kidney disease.
The recommended starting dose of FILSPARI® is 200 mg once daily.
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- mailbox：info@lucius.la
